As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.

With seven COVID-19 treatment/prophylactic candidates lined up, India's Zydus Cadila is unleashing all it can to combat the disease. Meanwhile, the firm has also offered an update on the state of its injectables and transdermals business in the US, which is contingent on resolving deficiencies at its Moraiya plant.

With seven COVID-19 treatment/prophylactic candidates lined up, India's Zydus Cadila is unleashing all it can to combat the disease. While Phase III data for its DNA vaccine candidate is expected by April, the latest to join the pack is ZYIL1, a novel oral small molecule NLRP3 inhibitor.

Novavax aims to recruit 10,000 subjects in the UK, and will include a flu vaccination co-administration for some participants.